SEATTLE, WA--(Marketwire - March 11, 2008) - Calistoga Pharmaceuticals, Inc., an early stage clinical company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase I clinical trial of CAL-101, a novel orally-available small molecule inhibitor of an important intracellular signaling component known as phosphoinositide-3 kinase (PI3K) delta.
